Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:52:04.250Z.
Calculation as of: 2026-10-06T15:52:04.250Z.
Quote observation: 2026-10-06T15:49:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 564e985820cc4d82a577ec1dab8a2942c5d07d58deba224fe20754c365e89b20
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Pulmonx Corporation
Market Cap
$79.98M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Pulmonx Corporation (LUNG) | $79.98M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $82.26M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A |
| Nutriband Inc. (NTRB)vs › | $80.47M | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.57M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.75M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.47M | N/A |
| Outset Medical, Inc. (OM)vs › | $75.82M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
